ClinicalTrials.gg
Status unknownNCT05313425Updated Apr 6, 2022

Effect of Ectoine After Photorefractive Keratectomy (PRK).

An observational study in Photorefractive Keratectomy and Corneal Haze, sponsored by Tanta University. Status unknown at 1 site in Egypt. Open to participants aged 19 Years to 35 Years. Per ClinicalTrials.gov, last updated 2022-04-06.

Sponsored by Tanta University · Observational

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
15
Ages
19 Years to 35 Years
Sex
All
01

Study summary

This is a comparative, open label, parallel group, non interventional study aims to assess the effect of Ectoine containing eye drops on stromal haze, pain and epithelial healing after Photorefractive keratectomy (PRK). The patient apply Ectohylo eye drops (Ectoine +Sodium Hyauronate) in the right eye and Polyfresh Extra eye drops (Carboxymethyl cellulose + Sodium Hyauronate ) in the left eye plus the routine post PRK treatment in both eyes. Post operative pain , epithelial healing and corneal densitometry is observed in both eyes.

Read the detailed description

Photorefractive keratectomy (PRK) is a commonly used operation for laser vision correction. The main fears of this type of laser vision correction is corneal haze, delayed epithelial healing and postoperative severe pain. Ectoine is a natural compound that has the ability to protect biological membranes from damage and environmental effects. This study assess the use of Ectoine containing eye drops to protect the bare ocular surface and reduce inflammation after PRK that will inturn is expected to affect the post operative corneal haze, pain, and epithelial healing .

02

Conditions studied

  • Photorefractive Keratectomy
  • Corneal Haze

Browse trials for

Keywords

  • PRK, surface ablation, corneal haze
03

In context

Corneal Opacity

37 studies on the registry are indexed under Corneal Opacity; 5 are open to participants now.

This study's planned enrollment of 15 is below the median of 45 across 14 observational studies indexed under Corneal Opacity.

Browse Corneal Opacity studies →

Lead sponsor

Tanta University is the lead sponsor of 1,010 studies on the registry; 321 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient enrolled for photorefractive keratectomy for correction of myopia and myopic astigmatism.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient undergoing PRK for myopia and myopic astigmatism when astigmatism is 2.5 diopters or less and myopia with spherical equivalent -4 or less.

Exclusion criteria

Exclusion Criteria:

  • patient spherical equivalent more myopic than -4 diopters
  • Patients with astigmatism more than 2.5 diopter
  • Patients with anisometropia ( difference > 2 diopters)
  • Patient with previous ocular surgery
  • Patients with chronic systemic disease that can affect results of laser vision correction (e.g. rheumatoid arthritis)
  • Pregnant and lactating females
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ectoine Eye

    The right eye of the studied group will be given 2% Ectoine containig , 0.2% sodium hyaluronate eye drops(Ectohylo) hourly.

    Other: Ectohylo (R) eye drops

  • Control eye

    The left eye of the studied group will be give Carboxymethyl cellulose, 0.2% sodium hyaluronate eye drops(Polyfresh Extra) hourly.

Interventions

  • OtherEctohylo (R) eye drops

    using Ectohylo eye drops post operative after PRK in the right eyes of the patients

    Also known as: Ectoine 2% eye drops

06

What researchers measure

Primary outcomes

  1. Corneal Densitometry (assesed by Pentacam).

    Post photo refractive keratectomy early haze (3 months after operation) assesed by Pentacam densitometry

    Time frame: 3 months post operative

Secondary outcomes

  1. Pain score (0 -10)

    pain in the first 2 days post operative (graded 0 to 10)

    Time frame: 2 days

  2. Time of Epithelial healing (days)

    Time required for epithelial healing after PRK in days

    Time frame: 2-7 days

07

Study locations

1 of 1 sites recruiting
  • Tanta University
    Tanta, El Gharbia 31512, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interest in Cornea. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: after publication for 5 months

Access criteria: Authorized Ophthalmologists specialized in cornea and refractive surgery

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05313425
Lead sponsor
Tanta University
Responsible party
Mohamed Elkadim (Lecturer of ophthalmology, Tanta University) — Principal investigator
First posted
Apr 6, 2022
Start date
Jan 1, 2022
Primary completion
May 2022 (estimated)
Completion
Oct 2022 (estimated)
Last update
Apr 6, 2022

Study contacts

Mohamed Elkadim, MD
Contact
mzekadem@gmail.com
01004991183
Mohamed Elkadim
principal investigator · Tanta University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion